Authors
Latest:
Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLCHolger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).
Latest:
Dr. Nanus Discusses Adjuvant Therapy for RCCDavid M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.
Latest:
Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLCSarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.
Latest:
Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLCJames Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Pacheco on Frontline Therapy for Patients With EGFR-Mutant NSCLCJose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Latest:
Dr. Van Veldhuizen Discusses Combination Therapy in RCCPeter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.
Latest:
Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCCNeeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.
Latest:
More Data Are Needed For EGFR-Targeted Agents in NSCLCEdward B. Garon, MD, discusses the landscape of EGFR-targeted therapy in non–small cell lung cancer.
Latest:
Dr. Patel on Induction in Patients With Mantle Cell LymphomaKrish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).
Latest:
Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLCMichael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).
Latest:
Mario Sznol, MD, on Patient Selection for Combination Therapy in mRCCMario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.
Latest:
Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLCMartin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.
Latest:
Dr. McCulloch on the Use of R-BAC in MCL After Progression on BTK TherapyRory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the use of R-BAC (rituximab [Rituxan],bendamustine, and cytarabine) in patients with mantle cell lymphoma (MCL) who had progressed on initial therapy with a BTK inhibitor.
Latest:
Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCCRichard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).
Latest:
Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCCToni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.
Latest:
Dr. Mudad on RELAY Trial for EGFR-Mutant NSCLCRaja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.
Latest:
First-Line Necitumumab Improves Survival in Metastatic Squamous NSCLCA phase III trial exploring necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous non-small cell lung cancer has demonstrated an improvement in overall survival when compared to chemotherapy alone.
Latest:
Dr. Robert Motzer Reviews the Phase III COMPARZ StudyRobert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.
Latest:
Dr. Vogelzang Discusses First-Line Axitinib in mRCCNicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.
Latest:
Dr. Bollard on the Treatment of EBV-Positive LymphomaCatherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.
Latest:
Dr. Sarah Holstein on Lenalidomide Maintenance UpdatesSarah Holstein, MD, PhD, Assistant Professor of Oncology, Lymphoma/Myeloma Service Department of Medicine, Roswell Park Cancer Institute, discusses an updated of analysis CALGB/ECOG/BMT CTN 100104, which investigated lenalidomide maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma.
Latest:
Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell CarcinomaBrian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.
Latest:
Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALLStephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).
Latest:
Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCCMark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.
Latest:
Investigators Seek Expanded Use of Checkpoint Inhibitors in RCCIn contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.
Latest:
Dr. Cavo on Upfront ASCT in Multiple MyelomaMichele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.
